vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and Root, Inc. (ROOT). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $397.0M, roughly 1.8× Root, Inc.). On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 21.5%). Over the past eight quarters, Root, Inc.'s revenue compounded faster (24.8% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Root Insurance Company is an online car insurance company operating in the United States.
MEDP vs ROOT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $397.0M |
| Net Profit | $135.1M | — |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 2.6% |
| Net Margin | 19.1% | — |
| Revenue YoY | 32.0% | 21.5% |
| Net Profit YoY | 15.5% | — |
| EPS (diluted) | $4.65 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $397.0M | ||
| Q3 25 | $659.9M | $387.8M | ||
| Q2 25 | $603.3M | $382.9M | ||
| Q1 25 | $558.6M | $349.4M | ||
| Q4 24 | $536.6M | $326.7M | ||
| Q3 24 | $533.3M | $305.7M | ||
| Q2 24 | $528.1M | $289.2M | ||
| Q1 24 | $511.0M | $254.9M |
| Q4 25 | $135.1M | — | ||
| Q3 25 | $111.1M | $-5.4M | ||
| Q2 25 | $90.3M | $22.0M | ||
| Q1 25 | $114.6M | $18.4M | ||
| Q4 24 | $117.0M | — | ||
| Q3 24 | $96.4M | $22.8M | ||
| Q2 24 | $88.4M | $-7.8M | ||
| Q1 24 | $102.6M | $-6.2M |
| Q4 25 | 21.6% | 2.6% | ||
| Q3 25 | 21.5% | 0.1% | ||
| Q2 25 | 20.9% | 7.1% | ||
| Q1 25 | 20.3% | 6.8% | ||
| Q4 24 | 23.4% | 10.7% | ||
| Q3 24 | 21.1% | 11.3% | ||
| Q2 24 | 19.9% | 1.3% | ||
| Q1 24 | 20.4% | 2.1% |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 16.8% | -1.4% | ||
| Q2 25 | 15.0% | 5.7% | ||
| Q1 25 | 20.5% | 5.3% | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 18.1% | 7.5% | ||
| Q2 24 | 16.7% | -2.7% | ||
| Q1 24 | 20.1% | -2.4% |
| Q4 25 | $4.65 | $0.35 | ||
| Q3 25 | $3.86 | $-0.35 | ||
| Q2 25 | $3.10 | $1.29 | ||
| Q1 25 | $3.67 | $1.07 | ||
| Q4 24 | $3.67 | $1.42 | ||
| Q3 24 | $3.01 | $1.35 | ||
| Q2 24 | $2.75 | $-0.52 | ||
| Q1 24 | $3.20 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $669.3M |
| Total DebtLower is stronger | — | $200.3M |
| Stockholders' EquityBook value | $459.1M | $284.3M |
| Total Assets | $2.0B | $1.7B |
| Debt / EquityLower = less leverage | — | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $669.3M | ||
| Q3 25 | $285.4M | $653.3M | ||
| Q2 25 | $46.3M | $641.4M | ||
| Q1 25 | $441.4M | $609.4M | ||
| Q4 24 | $669.4M | $599.3M | ||
| Q3 24 | $656.9M | $674.8M | ||
| Q2 24 | $510.9M | $667.2M | ||
| Q1 24 | $407.0M | $640.5M |
| Q4 25 | — | $200.3M | ||
| Q3 25 | — | $200.4M | ||
| Q2 25 | — | $200.1M | ||
| Q1 25 | — | $200.0M | ||
| Q4 24 | — | $200.1M | ||
| Q3 24 | — | $300.9M | ||
| Q2 24 | — | $300.1M | ||
| Q1 24 | — | $299.3M |
| Q4 25 | $459.1M | $284.3M | ||
| Q3 25 | $293.6M | $265.0M | ||
| Q2 25 | $172.4M | $244.5M | ||
| Q1 25 | $593.6M | $228.7M | ||
| Q4 24 | $825.5M | $203.7M | ||
| Q3 24 | $881.4M | $181.9M | ||
| Q2 24 | $763.6M | $151.3M | ||
| Q1 24 | $671.5M | $165.7M |
| Q4 25 | $2.0B | $1.7B | ||
| Q3 25 | $1.8B | $1.6B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.9B | $1.6B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $2.1B | $1.6B | ||
| Q2 24 | $1.9B | $1.5B | ||
| Q1 24 | $1.8B | $1.4B |
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.98× | ||
| Q3 24 | — | 1.65× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | — | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $206.5M |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $206.5M | ||
| Q3 25 | $246.2M | $57.6M | ||
| Q2 25 | $148.5M | $52.0M | ||
| Q1 25 | $125.8M | $26.8M | ||
| Q4 24 | $190.7M | $195.7M | ||
| Q3 24 | $149.1M | $49.4M | ||
| Q2 24 | $116.4M | $62.6M | ||
| Q1 24 | $152.7M | $14.5M |
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | $195.3M | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | $62.4M | ||
| Q1 24 | $147.2M | $14.3M |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | 59.8% | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | 21.6% | ||
| Q1 24 | 28.8% | 5.6% |
| Q4 25 | 0.6% | 0.0% | ||
| Q3 25 | 1.6% | 0.0% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 1.8% | 0.0% | ||
| Q4 24 | 1.4% | 0.1% | ||
| Q3 24 | 2.0% | 0.0% | ||
| Q2 24 | 2.4% | 0.1% | ||
| Q1 24 | 1.1% | 0.1% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | 2.36× | ||
| Q1 25 | 1.10× | 1.46× | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | 2.17× | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
ROOT
Segment breakdown not available.
